Asad Haider, an analyst from Goldman Sachs, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The associated price target remains the same with $176.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Asad Haider has given his Buy rating due to a combination of factors that highlight Johnson & Johnson’s strong market position and growth potential. The recent Digestive Disease Week showcased JNJ’s advancements, particularly with Tremfya, which is gaining traction in the Inflammatory Bowel Disease (IBD) market. The product’s rapid growth in ulcerative colitis and its favorable reception by key opinion leaders (KOLs) underscore its commercial success.
Furthermore, the subcutaneous administration of Tremfya is seen as a significant advantage, facilitating quicker patient onboarding and streamlining office workflows. The lack of payor resistance and the potential for patient switches from other treatments to Tremfya further bolster its market prospects. Additionally, JNJ’s strong performance in the first quarter of 2025, where Tremfya exceeded consensus expectations, reinforces the positive outlook for the company’s pharmaceutical franchise.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $181.00 price target.
JNJ’s price has also changed slightly for the past six months – from $153.240 to $148.440, which is a -3.13% drop .